Surgical Quality Improvement

Brain Tumor Surgery Outcomes

Brain Tumor Surgery ACS NSQIP Outcomes

January 1, 2024– December 31, 2024

The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall brain tumor surgery ACS NSQIP performance benchmarked against 222 participating sites.

Brain Tumor (222 Sites)NObservedExpected
30 Day Mortality3161.90%1.69%
30 Day Morbidity31612.03%8.45%
Unplanned Intubation3163.48%1.59%
Ventilator > 48 Hours3143.82%1.21%
Deep Vein Thrombosis (DVT) / Pulmonary Embolus3163.16%2.73%
Renal Failure3160.95%0.31%
Urinary Tract Infection (UTI)3152.22%1.19%
Surgical Site Infection (SSI)3162.22%1.88%
Sepsis3161.27%1.09%
C.diff Colitisᵃ3161.58%0.17%
Unplanned Reoperation3163.80%4.20%
Length of Stayᵇ27010.00%22.55%
Unplanned Readmission3169.49%9.18%

American College of Surgeons National Surgical Quality Improvement Program, 2025.
ACS NSQIP® Semiannual Report July, 2025, Chicago: American College of Surgeons.

ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.

ᵇIdentified as a statistical outlier (lower than expected) by the ACS NSQIP hierarchical model.